Access and use of WHO essential medicines in Italy.
drug consumption
essential medicines
expenditure
health policy
national formulary
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
04
2023
accepted:
13
09
2023
medline:
27
10
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
Many countries use the WHO Essential Medicines List (EML) as a guide for health policy choices to promote the efficient use of healthcare resources or adopt the concept of essential medicines (EMs) to develop their own national list of essential medicines. The aim of this study is to analyse the availability and use of medicines included in the 22nd WHO EML in Italy. Using the ATC code (5th level), a comparison was made between the medicines included in the WHO EML and those retrieved from the Italian Medicines Agency (AIFA) database. The availability (regulatory and reimbursement status) of EMs, as well as the market share in expenditure (million euros) and consumption [measured in WHO-defined daily doses (DDDs)], compared to all reimbursed medicines in 2021, were analysed. In 2021, approximately 85.2% ( In Italy, high coverage of EMs was found. It was largely reimbursed by the INHS, even when compared to other European countries. Essential medicines represented a high percentage of the overall expenditure and consumption in Italy. The WHO EML could be an important tool to guide the health policy choices of high-income countries, although a more frequent update and easier access to information on rejected medicines are needed.
Sections du résumé
Background
Many countries use the WHO Essential Medicines List (EML) as a guide for health policy choices to promote the efficient use of healthcare resources or adopt the concept of essential medicines (EMs) to develop their own national list of essential medicines. The aim of this study is to analyse the availability and use of medicines included in the 22nd WHO EML in Italy.
Methods
Using the ATC code (5th level), a comparison was made between the medicines included in the WHO EML and those retrieved from the Italian Medicines Agency (AIFA) database. The availability (regulatory and reimbursement status) of EMs, as well as the market share in expenditure (million euros) and consumption [measured in WHO-defined daily doses (DDDs)], compared to all reimbursed medicines in 2021, were analysed.
Results
In 2021, approximately 85.2% (
Conclusions
In Italy, high coverage of EMs was found. It was largely reimbursed by the INHS, even when compared to other European countries. Essential medicines represented a high percentage of the overall expenditure and consumption in Italy. The WHO EML could be an important tool to guide the health policy choices of high-income countries, although a more frequent update and easier access to information on rejected medicines are needed.
Identifiants
pubmed: 37881343
doi: 10.3389/fpubh.2023.1211208
pmc: PMC10595003
doi:
Substances chimiques
Antineoplastic Agents
0
Drugs, Essential
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1211208Informations de copyright
Copyright © 2023 Petrella, Fortinguerra, Cangini, Pierantozzi and Trotta.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMJ Open. 2022 Feb 10;12(2):e053349
pubmed: 35144950
Bull World Health Organ. 2019 Jun 01;97(6):394-404C
pubmed: 31210677
Lancet. 2017 Jan 28;389(10067):403-476
pubmed: 27832874
CMAJ Open. 2017 Feb 16;5(1):E137-E143
pubmed: 28401130
PLoS One. 2015 Dec 09;10(12):e0143654
pubmed: 26650544
J Med Chem. 2020 Sep 24;63(18):10170-10187
pubmed: 32352778
BMJ Open. 2021 Aug 11;11(8):e045262
pubmed: 34380717
PLoS One. 2014 Oct 22;9(10):e111474
pubmed: 25337860
Basic Clin Pharmacol Toxicol. 2018 Apr;122(4):402-412
pubmed: 29117642
JAMA. 2022 Nov 8;328(18):1807-1808
pubmed: 36279114
Indian J Community Med. 2010 Jan;35(1):10-3
pubmed: 20606912
Eur J Clin Pharmacol. 2015 Jul;71(7):825-33
pubmed: 25956715
BMJ. 2023 Sep 5;382:e076783
pubmed: 37669797